




TN Ferade™ Cancer Therapeutic

A First-in-Class, Phase II/III Cancer Product Candidate with Broad Application - Pancreatic Cancer is Lead Indication – Defined Regulatory Pathway


TN Ferade is designed for use in combination with standard radiation and/or chemotherapy to provide sustained levels of Tumor Necrosis Factor Alpha (TNF- α) protein within tumors. A highly effective TNF- α protein product (Beromun® - Boehringer-Ingelheim) is approved in Europe to treat soft tissue sarcomas, but has limited utility as it must be administered by isolated limb perfusion to avoid systemic toxicity. TN Ferade solves this problem by using a gene to trigger production of the protein in the tumor, broadening its utility to a variety of cancer types. It is readily manufactured, stored and administered.




Addresses Unmet Medical Needs – This investigational drug is being developed to improve the treatment of a variety of cancers. The lead indication is currently pancreatic cancer. Patients with locally advanced, non-metastatic disease have no available effective treatment options. The disease presents with a 98% mortality rate. TN Ferade has shown promise in this and other solid tumors, including esophageal, rectal cancer and melanoma.

Program is De-risked—The underlying delivery technology has been proven safe in thousands of patients, and the effectiveness of TNF- α protein is well established pre-clinically, and with Boehringer-Ingelheim’s marketed product, Beromun®. TN Ferade itself has demonstrated an excellent safety profile and compelling activity in human testing, and is manufacturable at scale. The approach is endorsed by regulatory agencies and a clear and viable pathway to commercialization has been established.


TN Ferade™ - Broad Activity in Multiple Tumor Types Seen in Phase I



TN Ferade - Histopathologic Response in Large Tumors - Phase 1 Sarcoma Study



TN Ferade™ Phase II Results Pancreatic Cancer



Commercial Opportunity – The GI cancer market alone involves about 1 million new cases annually. GI indications represent only a fraction of this investigational drug’s demonstrated potential, and easily represent a \$1 billion market in the US, much larger world-wide. Strategies to access the even larger and broader markets of solid tumors will further enhance the commercial potential of TN Ferade. Pricing analogs include Tarceva, priced at \$21,000 per treatment course, Avastin at \$85,000 per treatment course, and Erbitux at \$96,000 per treatment course.



Nasdaq: GNVC

www.genvec.com